There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Fibroadenomas are the commonest benign breast tumours. Prior to vacuum-assisted large-volume
biopsy, surgical excision was the only therapeutic option available. Our unit introduced
Mammotome (Ethicon Endo-Surgery, Cincinnati, OH, USA) in January 2006, with Mammotome
excision offered from September 2006 (for lesions 25 mm or less). We reviewed the
change in practice with the advent of Mammotome.
Patients with histological diagnosis of fibroadenoma throughout 2006 and 2007 were
identified. The radiology and histology were reviewed.
A total of 355 fibroadenomas were diagnosed in 333 patients: 252 presented symptomatically,
81 were screen-detected.
Thirty-five diagnostic Mammotomes were performed (33 had been nondiagnostic on needle-core
biopsy, two had radiology/pathology discordance). Definitive diagnosis was consequently
made in 34 cases. One patient with nondiagnostic Mammotome had subsequent surgical
biopsy of benign fibroadenoma.
Seventy patients underwent excision. Fifteen were ultrasound Mammotome excisions;
13 confirmed fibroadenoma and two were phylloides (having surgical cavity excision
subsequently). Fifty-five were surgical excisions; 33 were either unsuitable for Mammotome
excision or the patient chose surgery; 11 were B2/B3 lesions and pathology recommended
surgical excision; and the remaining 11 were before the introduction of Mammotome
excision.
Mammotome offers patient choice regarding excision of fibroadenomas, and reduces the
number of surgical biopsies.